10.3 Circadian Rhythm Sleep-Wake Disorders & Light Therapy

10.3 Circadian Rhythm Sleep-Wake Disorders & Light Therapy

Quick Answer: Circadian Rhythm Sleep-Wake Disorders (CRSWD) stem from persistent misalignment between the endogenous master circadian pacemaker (the suprachiasmatic nucleus, SCN) and the external 24-hour physical and social environment. Under ICSD-3, major subtypes include Delayed Sleep-Wake Phase Disorder (DSWPD; sleep delayed $\ge 2$ hours, prevalent in adolescents), Advanced Sleep-Wake Phase Disorder (ASWPD; sleep advanced $\ge 2$ hours, common in older adults), Non-24-Hour Sleep-Wake Rhythm Disorder (free-running, predominantly affecting totally blind individuals due to loss of ipRGC photic signaling, treated with tasimelteon), Shift Work Disorder, Jet Lag Disorder, and Irregular Sleep-Wake Rhythm Disorder. Clinical evaluation uses at least 7 (preferably 14) days of sleep logs and actigraphy, supported by Dim Light Melatonin Onset (DLMO) testing. Treatment utilizes chronotherapy based on Phase Response Curves (PRC): morning bright light (10,000 lux) and late-afternoon low-dose melatonin (0.5–3 mg) induce a phase advance for DSWPD, whereas evening bright light induces a phase delay for ASWPD.

Human sleep-wake timing is governed by the intricate interplay between homeostatic sleep pressure (Process S) and the endogenous circadian timing system (Process C). When an individual's internal circadian clock desynchronizes from astronomical day-night cycles or obligatory social schedules, Circadian Rhythm Sleep-Wake Disorders (CRSWDs) develop, resulting in severe chronic insomnia, daytime hypersomnolence, and impaired metabolic and cardiovascular health.

---

Circadian Basics in Brief

The suprachiasmatic nucleus (SCN) has an intrinsic period of about 24.2 hours and is reset daily, mainly by light reaching melanopsin-containing retinal ganglion cells; pineal melatonin signals biological night. The circadian biology section earlier in this guide covers the pathway, DLMO and phase response curves in detail. For the disorders below, two rules matter most: light after the core temperature minimum (morning) advances the clock and light before it (evening) delays it, while melatonin works in roughly the opposite pattern.

---

ICSD-3 Classification of CRSWD Subtypes

1. Delayed Sleep-Wake Phase Disorder (DSWPD)

• Clinical Characteristics: Characterized by a stable, intractable delay in the timing of the major sleep period, usually by 2 or more hours relative to conventional or desired sleep times. Bedtimes typically range from 02:00 to 06:00 AM, with preferred rise times between 10:00 AM and 02:00 PM.
• The Core CCSH Diagnostic Pearl: Sleep architecture, total sleep time, and sleep quality are entirely normal when the patient is permitted to sleep on their naturally delayed schedule (such as during vacations or unstructured weekends). However, when forced to awaken early for conventional school or work, they suffer severe sleep-onset insomnia, chronic sleep deprivation, and profound morning sleep inertia ("sleep drunkenness"). This chronic discrepancy between biological and social time is termed social jetlag.
• Epidemiology & Genetics: Highly prevalent in adolescents and young adults (7% to 16%). Associated with a biological lengthening of circadian period ($\tau$), evening chronotype, and polymorphisms in the core clock gene PER3 (variable number tandem repeat polymorphism) or CRY1 mutations.

2. Advanced Sleep-Wake Phase Disorder (ASWPD)

• Clinical Characteristics: The habitual sleep-wake cycle is advanced by 2 or more hours earlier than conventional societal norms. Typical sleep onset occurs between 18:00 and 21:00 (6:00–9:00 PM), with spontaneous, involuntary awakening between 02:00 and 05:00 AM.
• Clinical Presentation: Patients present complaining of severe early evening somnolence (falling asleep during social gatherings or family dinners) and early morning awakening (terminal insomnia). When awakened in the early morning, they feel alert and unable to return to sleep.
• Epidemiology & Genetics: More common in older adults, in whom an age-related phase advance, less daytime light and a blunted circadian amplitude contribute (aging does not clearly shorten tau). A rare familial form, Familial Advanced Sleep Phase Syndrome (FASPS), displays autosomal dominant inheritance linked to missense mutations in human PER2 (hPer2) or casein kinase 1 delta (CSNK1D / CK1 delta).

3. Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD / Free-Running)

• Clinical Characteristics: The endogenous circadian pacemaker fails to entrain to the 24-hour solar day, so the clock free-runs at its intrinsic period, which is usually a little longer than 24 hours (about 24.1–24.5 hours in blind patients and sometimes longer in sighted patients).
• Clinical Trajectory: Because $\tau > 24.0$ hours, the internal biological sleep propensity drifts later each day, typically by about 10 to 30 minutes and sometimes more. As the circadian cycle slowly rotates around the 24-hour clock, the patient experiences cyclical phases:
  • In-Phase Weeks: When internal biological sleep coincides with environmental night, sleep is sound and daytime alertness is normal.
  • Out-of-Phase Weeks: Weeks later, biological sleep propensity drifts into the daytime hours, causing intractable nighttime insomnia and overwhelming daytime somnolence.
• Primary Patient Population: Overwhelmingly affects totally blind individuals who lack conscious light perception and functional ipRGC signaling, severing the photic entrainment pathway. It is occasionally observed in sighted individuals with severe psychiatric conditions or neurodevelopmental disorders.
• Targeted Pharmacotherapy: Tasimelteon, an oral dual melatonin MT1 and MT2 receptor agonist, is FDA-approved specifically for the treatment of Non-24-Hour Sleep-Wake Disorder in totally blind patients to facilitate circadian entrainment.

4. Shift Work Disorder (SWD)

• Clinical Characteristics: Characterized by complaints of insomnia and/or excessive daytime sleepiness that are temporally associated with a recurring work schedule that overlaps the habitual sleep period (night shifts, rotating shifts, early morning shifts starting between 04:00 and 07:00 AM).
• Pathophysiology: Chronic desynchrony between the endogenous SCN circadian alerting signal and the required sleep schedule. When night-shift workers attempt daytime sleep, daytime circadian alerting forces, higher core body temperature, ambient noise, and domestic responsibilities truncate total sleep time by 1 to 4 hours, resulting in chronic cumulative sleep debt.
• Morbidity: Shift work disorder is associated with elevated rates of motor vehicle collisions during morning commutes, industrial operational errors, metabolic syndrome, type 2 diabetes, peptic ulcer disease, cardiovascular morbidity, depression, and increased cancer risk (classified as a Group 2A probable human carcinogen by the IARC).

5. Jet Lag Disorder

• Clinical Characteristics: A temporary desynchronization between the internal circadian clock and local environmental time following rapid transmeridian travel across two or more time zones.
• Directional Asymmetry:
  • Eastward Travel (Phase Advance Required): Eastward travel requires advancing the circadian clock (shortening the day), which is biologically significantly more difficult. Adapting to an eastward flight requires approximately 1.5 days per time zone crossed.
  • Westward Travel (Phase Delay Required): Westward travel requires delaying the circadian clock (lengthening the day), which is substantially easier because the intrinsic human circadian period naturally runs slightly longer than 24 hours ($\tau \approx 24.2$ hr). Adapting requires approximately 1.0 day per time zone crossed.
• Symptoms: Sleep-onset or sleep-maintenance insomnia, daytime fatigue, cognitive clouding, gastrointestinal disturbances (anorexia, altered bowel habits), and general somatic malaise.

6. Irregular Sleep-Wake Rhythm Disorder (ISWRD)

• Clinical Characteristics: A severe breakdown of the circadian sleep-wake architecture, resulting in the total absence of a discernible 24-hour sleep-wake pattern. Sleep is fragmented into at least three or more distinct bouts scattered haphazardly throughout the 24-hour day, although total 24-hour sleep time may remain normal for age.
• Associated Pathology: Heavily concentrated in institutionalized elderly patients with severe neurodegenerative disorders (Alzheimer's disease, Lewy body dementia), pediatric neurodevelopmental disabilities, or severe traumatic brain injury. Driven by structural SCN neuronal degeneration and lack of structured social and photic zeitgebers.

---

Diagnostic & Clinical Assessment Modalities

Accurate diagnosis of CRSWDs cannot be established via single-night polysomnography. Clinical practice standards mandate longitudinal evaluation:

1. Daily Sleep Logs / Diaries

Patients complete sleep logs for at least 7 days and preferably 14 or more (ICSD-3), documenting sleep-wake patterns across both scheduled (work/school) days and non-scheduled (free/vacation) days.

2. Continuous Wrist Actigraphy

Wrist actigraphy, usually on the non-dominant wrist, for at least 7 and preferably 14 days is the recommended objective measure (AASM 2018 actigraphy guideline), ideally covering both work and free days. Actigraphy utilizes piezoelectric accelerometers to record movement, providing validated rest-activity data that objectively confirms phase delays, phase advances, circadian day-to-day drift (free-running patterns), or total circadian fragmentation.

3. Dim Light Melatonin Onset (DLMO)

Dim Light Melatonin Onset (DLMO) represents the most reliable, validated biological marker of endogenous circadian phase:

• Testing Protocol: Salivary or plasma samples are collected in dim ambient light ($< 10\text{ lux}$) every 30 to 60 minutes, beginning 4 to 5 hours prior to the patient's habitual sleep onset and continuing until 1 hour after habitual sleep onset.
• Clinical Interpretation: DLMO marks the precise time point at which endogenous melatonin production surges above a threshold (typically $>4\text{ pg/mL}$ in saliva or $>10\text{ pg/mL}$ in plasma). In healthy adults, DLMO occurs approximately 2 hours prior to habitual sleep onset (typically between 20:00 and 22:00). In DSWPD, DLMO is delayed past midnight or early morning hours.

---

Chronotherapy & Photic Phase-Shifting Protocols

Modulating circadian phase relies on understanding the Phase Response Curve (PRC) to light and exogenous melatonin. The direction and magnitude of a phase shift depend entirely on the biological timing of administration relative to the core body temperature minimum ($T_{\min}$), which normally occurs approximately 2 hours before spontaneous morning awakening (around 04:30–05:00 AM in a normal sleeper):

       Phase Response Curve (PRC) Dynamics:
──────────────────────────────────────────────────────────────────────────
Modality            Administration Timing              Circadian Phase Shift
──────────────────────────────────────────────────────────────────────────
Bright Light        Biological Morning (After Tmin)    PHASE ADVANCE (Earlier)
Bright Light        Biological Evening (Before Tmin)   PHASE DELAY (Later)
Exogenous Melatonin Late Afternoon / Early Evening     PHASE ADVANCE (Earlier)
Exogenous Melatonin Biological Morning                 PHASE DELAY (Later)
──────────────────────────────────────────────────────────────────────────

1. Bright Light Therapy Protocol

• Equipment Specifications: Certified light box providing 10,000 lux of broad-spectrum white light (or equivalent narrow-band blue/blue-enriched light at ~460–480 nm with lower lux requirements) equipped with a diffuser that blocks harmful ultraviolet (UV) radiation.
• Positioning: Positioned at a distance of 30 to 45 cm (12 to 18 inches) from the eyes, angled at approximately 45 degrees so light enters the retina indirectly without staring into the bulbs.
• Duration: Typically 30 to 60 minutes daily.
• Protocol for DSWPD (Phase Advance):
  • Administer 10,000 lux bright light for 30 to 45 minutes immediately upon morning waking. If the patient's habitual wake time is 11:00 AM, begin light exposure at 11:00 AM and advance the waking/light time by 15 to 30 minutes every 2 to 3 days until the desired waking time is reached.
  • Concurrently enforce strict evening light restriction: dim indoor lights 2 hours before target bedtime, install blue-light filtering software on electronics, or wear amber blue-blocking glasses in the evening.
• Protocol for ASWPD (Phase Delay):
  • Administer 10,000 lux bright light in the early evening (typically 19:00 to 20:30 / 7:00–8:30 PM) to suppress early melatonin release, delay SCN phase, and push sleep onset later into the night.

2. Exogenous Melatonin Phase-Shifting Protocols

• Dosing Strategy: For chronobiological phase-shifting, low physiological doses (0.5 mg to 3 mg) are significantly more effective than high pharmacological doses (5 to 10 mg). High doses saturate MT1 and MT2 receptors for extended hours, spilling into morning hours and causing prolonged sedation and paradoxical phase delays.
• DSWPD Protocol (Phase Advance): Administer low-dose melatonin (0.5 mg to 3 mg) in the late afternoon or early evening, approximately 5 to 7 hours before habitual sleep onset (or ~2 to 3 hours prior to DLMO). This creates a powerful synergistic phase advance when combined with morning bright light.
• Shift Work Countermeasures: Night workers should wear dark sunglasses during the morning commute home to prevent bright sunlight from triggering a morning phase advance, sleep in a dark room during the day, and consider low-dose melatonin prior to daytime sleep.

---

3. Chronotherapy (Sleep-Schedule Shifting)

The blueprint lists chronotherapy separately from light therapy. Classic chronotherapy for DSWPD (Czeisler and colleagues, 1981) moves bedtime later by about 3 hours each day, going around the clock until the patient reaches the target bedtime, and then holds that schedule strictly. It works with the clock's natural tendency to drift later. However, it disrupts work or school for about a week, demands strict adherence afterward, and case reports describe patients who developed Non-24-hour sleep-wake rhythm disorder after it. The AASM's 2015 circadian guideline found too little evidence to recommend it. In practice, clinicians more often move the wake time and bedtime earlier by 15–30 minutes every few days, combined with morning light and timed melatonin.

Comprehensive Classification & Comparison of CRSWD Subtypes